Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
26.97
-0.74 (-2.67%)
At close: Sep 12, 2025, 4:00 PM EDT
27.02
+0.05 (0.17%)
After-hours: Sep 12, 2025, 6:24 PM EDT
Alkermes Revenue
Alkermes had revenue of $390.66M in the quarter ending June 30, 2025, a decrease of -2.12%. This brings the company's revenue in the last twelve months to $1.51B, down -0.17% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.51B
Revenue Growth
-0.17%
P/S Ratio
2.93
Revenue / Employee
$836,276
Employees
1,800
Market Cap
4.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALKS News
- 1 day ago - Alkermes Appoints Joshua Reed as Chief Financial Officer - PRNewsWire
- 2 days ago - Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program - PRNewsWire
- 5 days ago - Alkermes Plc (ALKS) World Sleep Congress 2025 (Transcript) - Seeking Alpha
- 5 days ago - Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 - PRNewsWire
- 19 days ago - Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025 - PRNewsWire
- 6 weeks ago - Alkermes: A More Than Solid Quarter - Seeking Alpha
- 6 weeks ago - Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Alkermes plc Reports Second Quarter 2025 Financial Results - PRNewsWire